Investigating people with mucocutaneous bleeding suggestive of primary hemostatic defects: A low likelihood of a definitive diagnosis?

Haematologica

Volumn 92, Issue 3, 2007, Pages 292-296

  Favaloro, Emmanuel J ^a  

^a WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOIMMUNE DISEASE; BERNARD SOULIER DISEASE; BLEEDING TIME; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BLOOD DISEASE; DIAGNOSTIC ERROR; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST; DISEASE SEVERITY; DYSFIBRINOGENEMIA; EDITORIAL; EPISTAXIS; GEOGRAPHY; GLANZMANN DISEASE; HEMATOMA; HEMOPHILIA; HEMOSTASIS; HUMAN; LABORATORY TEST; MALIGNANT NEOPLASTIC DISEASE; MENORRHAGIA; PHYSICAL EXAMINATION; POSTOPERATIVE HEMORRHAGE; PREVALENCE; QUESTIONNAIRE; SKIN BLEEDING; THROMBOCYTE DYSFUNCTION; VON WILLEBRAND DISEASE; ANAMNESIS; BLEEDING; BLEEDING DISORDER; BLOOD CLOTTING PARAMETERS; CASE CONTROL STUDY; CASE MANAGEMENT; CLASSIFICATION; FORECASTING; GENETICS; HOSPITALIZATION; INSTRUMENTATION; METHODOLOGY; MUCOSA; NOTE; PREDICTION AND FORECASTING; PROSPECTIVE STUDY; SKIN DISEASE; THROMBOCYTE DISORDER;

BLOOD PLATELET DISORDERS; CASE MANAGEMENT; CASE-CONTROL STUDIES; COAGULATION PROTEIN DISORDERS; FORECASTING; HEMORRHAGE; HEMORRHAGIC DISORDERS; HUMANS; MEDICAL HISTORY TAKING; MUCOUS MEMBRANE; PLATELET FUNCTION TESTS; PREDICTIVE VALUE OF TESTS; PREVALENCE; PROSPECTIVE STUDIES; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; SKIN DISEASES; VON WILLEBRAND DISEASE;

EID: 34247637309     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.11231     Document Type: Editorial

References (39)

1. Rodeghiero F, Castaman G, Tosetto A, Batlle J, Baudo F, Cappelletti A, et al. The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study. J Thromb Haemost 2005;3:2619-26.
2. Quiroga T, Goycoolea M, Panes O, Aranda E, Martínez C, Belmont S, et al. High prevalence of bleeders of unknown cause among patients with inherited mucocutaneous bleeding. Prospective study of 280 patients and 299 controls. Haematologica 2007;92:356-64.
3. Kadir RA, Chi C. Women and von Willebrand disease: controversies in diagnosis and management. Semin Thromb Hemost 2006;32:605-15.
4. Kouides P. Aspects of the laboratory identification of von willebrand disease in women. Semin Thromb Hemost 2006;32:480-4.
5. Federici A. Diagnosis of inherited von Willebrand disease: a clinical perspective. Semin Thromb Hemost 2006; 32:555-65.
6. Teitel JM. Clinical approach to the patient with unexpected bleeding. Clin Lab Haematol 2000;22 Suppl 1:9-11.
7. Favaloro EJ. Laboratory Identification of von Willebrand disease: technical and scientific perspectives. Semin Thromb Hemost 2006;32:456-71.
8. Federici A. Management of inherited von Willebrand Disease in 2006. Semin Thromb Hemost 2006;32:616-20.
9. Tosetto A, Rodeghiero F, Castaman G, Goodeve A, Federici AB, Batlle J, et al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost 2006;4:766-73.
10. Koreth R, Weinert C, Weisdorf DJ, Key NS. Measurement of bleeding severity: a critical review. Transfusion 2004; 44:605-17.
11. Quiroga T, Goycoolea M, Munoz B, Morales M, Aranda E, Panes O, et al. Template bleeding time and PFA-100 have low sensitivity to screen patients with hereditary mucocutaneous hemorrhages: comparative study in 148 patients. J Thromb Haemost 2004;2:892-8.
12. Quiroga T, Goycoolea M, Giesen PL, Morales M, Munoz B, Aranda E, e al. Thrombin generation in platelet-poor plasma is normal in patients with hereditary mucocutaneous haemorrhages. Pathophysiol Haemost Thromb 2003;33:30-5.
13. Quiroga T, Pérez M, Rodríguez S, Muñoz B, Aranda E, Morales M, et al. Skin and mucous membrane hemorrhages: clinical assessment, study sequence and relative frequency of hereditary diseases of the hemostasis in a Chilean population. Rev Med Chil 1997;125:409-18.
14. Federici AB. Acquired von Willebrand syndrome: an underdiagnosed and misdiagnosed bleeding complication in patients with lymphoproliferative and myeloproliferative disorders. Semin Hematol 2006;43 Suppl 1:S48-58.
15. Federici AB, Rand JH, Bucciarelli P, Budde U, van Genderen PJ, Mohri H, et al. Subcommittee on von Willebrand Factor. Acquired von Willebrand syndrome: data from an international registry. Thromb Haemost 2000;84:345-9.
16. Michiels JJ, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, Budde U, et al. Immune-mediated Etiology of acquired von Willebrand syndrome in systemic lupus erythematosus and in benign monoclonal gammopathy: therapeutic implications. Semin Thromb Hemostas 2006;32:577-88.
17. Hassan AA, Kroll MH. Acquired disorders of platelet function. Hematology Am Soc Hematol Educ Program 2005;1: 403-8.
18. Shapiro AD. Platelet function disorders. Haemophilia 2000; 6 Suppl 1:120-7.
19. Koutts J. A short history of diagnostic tests for von Willebrand disease: In Memory of Barry Firkin (1930 to 2001) and Ted Zimmerman (1937 to 1988). Semin Thromb Hemostas 2006;32:445-55.
20. Favaloro EJ, Bonar B, Kershaw G, Sioufi J, Baker R, Hertzberg M, et al. Reducing errors in identification of von Willebrand disease: the experience of the Royal college of Pathologists of Australasia Quality Assurance Program. On behalf of the RCPA QAP in Haematology. Semin Thromb Hemostas 2006;32:505-13.
21. Favaloro EJ. Standardisation, regulation, quality assurance and emerging technologies in hemostasis: issues, controversies, benents and limitations. Semin Thromb Hemostas 2007;33:in press.
22. Nurden AT. Qualitative disorders of platelets and megakaryocytes. J Thromb Haemost 2005;3:1773-82.
23. Kottke-Marchant K, Corcoran G. The laboratory diagnosis of platelet disorders. Arch Pathol Lab Med 2002;126:133-46.
24. Hayward C, Eikelboom J. Platelet function testing: quality assurance. Semin Thromb Hemostas 2007;33: in press.
25. Adams M, Ward C, Thorn J, Bianchi A, Jones-Perrin E, Coghlan D, et al. Emerging technologies in haemostasis diagnostics: a report from the Australasian Society of Thrombosis and Haemostasis Emerging Technologies Group. Semin Thromb Hemostas 2007; 33: in press.
26. James P, Lillicrap D. Genetic testing for von Willebrand disease: the Canadian experience. Semin Thromb Hemostas 2006;32:546-52.
27. Sadler JE Von Willebrand disease type 1: a diagnosis in search of a disease. Blood 2003;101:2089-93.
28. Sadler JE, Mannucci PM, Berntorp E, Bochkov N, Boulyjenkov V, Ginsberg D, et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost 2000;84:160-74.
29. Toogeh G, Sharifian R, Lak M, Safaee R, Artoni A, Peyvandi F. Presentation and pattern of symptoms in 382 patients with Glanzmann thrombasthenia in Iran. Am J Hematol 2004;77:198-9.
30. Gupta M, Bhattacharyya M, Choudhry VP, Saxena R. Spectrum of inherited bleeding disorders in Indians. Clin Appl Thromb/Hemost 2005;11:325-30.
31. Favaloro EJ. Template bleeding time and PFA-100 have low sensitivity to screen patients with hereditary mucocutaneous hemorrhages: comparative study of 148 patients - a rebuttal. J Thromb Haemost 2004;2:2280-2.
32. Budde U, Drewke E, Mainusch K, Schneppenheim R. Laboratory diagnosis of congenital von Willebrand disease. Semin Thromb Hemost 2002;28:173-90.
33. Cattaneo M. Are the bleeding time and PFA-100 useful in the initial screening of patients with mucocutaneous bleedings of hereditary nature? J Thromb Haemost 2004; 2:890-1.
34. Favaloro EJ. The utility of the PFA-100 in identification of von Willebrand Disease: a concise review. Semin Thromb Hemost 2006;32:537-45.
35. Favaloro EJ. Utility of the PFA-100® for assessing bleeding disorders and monitoring therapy: a review of analytical variables, benefits and limitations. Haemophilia 2001;7: 170-9.
36. Favaloro EJ. Laboratory monitoring of therapy in von Willebrand disease: Efficacy of the PFA-100® and VWF:CB as coupled strategies. Semin Thromb Hemost 2006;6:566-76.
37. Hayward CPM, Rao AK, Cattaneo M. Congenital platelet disorders: overview of their mechanisms, diagnostic evaluation and treatment. Haemophilia 2006; 12 Suppl 3:128-36.
38. Lillicrap D, Nair SC, Srivastava A, Rodeghiero F, Pabinger I, Federici AB. Laboratory issues in bleeding disorders. Haemophilia 2006;12 Suppl 3:68-75.
39. Favaloro EJ, Lillicrap D, Lazzari MA, Cattaneo M, Mazurier C, Woods A, et al. von Willebrand disease: laboratory aspects of diagnosis and treatment. Haemophilia 2004;10 Suppl 4:164-8.